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Background: The association of inflammatory factors and the aqueous flare value with macular edema in branch
retinal vein occlusion (BRVO) patients remains unclear. The relationship between the aqueous flare value and the
vitreous fluid levels of vascular endothelial growth factor (VEGF), interleukin (IL)-6, monocyte chemotactic protein
(MCP)-1, soluble intercellular adhesion molecule 1 (sICAM-1), and soluble VEGF receptor-2 (sVEGFR-2) was evaluated
to investigate the role of inflammation in BRVO associated with macular edema. Aqueous flare values and the
vitreous levels of VEGF, IL-6, MCP-1, sICAM-1, and sVEGFR-2 were compared between previously untreated patients
with BRVO and patients with macular hole (MH).
Methods: Vitreous samples were obtained from 45 patients during vitreoretinal surgery (28 patients with BRVO and
17 with MH), and the levels of VEGF, IL-6, MCP-1, sICAM-1, and sVEGFR-2 were measured by enzyme-linked
immunosorbent assay. Retinal ischemia was evaluated by measuring the area of capillary non-perfusion using
fluorescein angiography and the Scion Image program. Aqueous flare values were measured with a laser flare meter
and macular edema was examined by optical coherence tomography.
Results: The median aqueous flare value was significantly higher in the BRVO group (12.1 photon counts/ms) than
in the MH group (4.5 photon counts/ms, P < 0.001). There were significant correlations between the aqueous flare
value and the vitreous levels of VEGF, IL-6, MCP-1, and sICAM-1 in the BRVO group (ρ = 0.54, P = 0.005; ρ = 0.56,
P = 0.004; ρ = 0.52, P = 0.006; and ρ = 0.47, P = 0.015, respectively). The aqueous flare value was also significantly
correlated with the foveal thickness in the BRVO group (ρ = 0.40, P = 0.037).
Conclusions: Inflammation may induce an increase of vascular permeability and disrupt the blood-aqueous barrier
via release of inflammatory factors (VEGF, IL-6, MCP-1, and sICAM-1) in BRVO patients with macular edema.Background
Branch retinal vein occlusion (BRVO) is a common ret-
inal vascular disease that is frequently associated with
macular edema, which is the chief reason for visual im-
pairment in BRVO patients. Occlusion of blood vessels
causes bleeding and accumulation of serous fluid, which
leading to edema. It is considered that inflammation de-
velops due to damage arising from this process. Intravit-
real injection of bevacizumab (a monoclonal antibody
targeting vascular endothelial growth factor (VEGF)) or
ranibizumab (an Fab fragment that binds and neutralizes
all isoforms of VEGF-A) has been reported to improve
macular edema in patients with BRVO [1,2]. However,* Correspondence: noma-hide@umin.ac.jp
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vitreal treatment with bevacizumab or ranibizumab [3,4],
suggesting that other vasoactive factors may contribute
to macular edema in addition to VEGF. We recently re-
ported that intraocular levels of inflammatory factors,
which are expressed by migrating leukocytes, glia cells,
and vascular endothelial cells, were significantly correlated
with the severity of macular edema in BRVO patients
[5,6], suggesting an important role for inflammation in the
occurrence of macular edema. This hypothesis is sup-
ported by the results of the Standard Care vs Corticoster-
oid for Retinal Vein Occlusion (SCORE) study, which
showed that intravitreal injection of triamcinolone aceto-
nide improved visual acuity and macular edema after
12 months in patients with BRVO [7]. Moreover, a larger
non-perfused area is associated with higher intraocular
levels of these inflammatory factors [5,6]. However, eventd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical and laboratory characteristics of the BRVO





Gender (Male/Female) 17/11 8/9 0.371
Age (yr) 71.2 ± 7.8‡ 68.9 ± 6.0‡ 0.304
Blood pressure (mmHg)
Systolic 135 ± 15‡ 115 ± 14‡ <0.001
Diastolic 80 ± 10‡ 71 ± 9‡ 0.004
Hypertension 17 2 0.001
Hyperlipidemia 7 4 0.911
Duration of BRVO (months) 4.7 ± 2.2‡ - -
Aqueous flare
(photon counts/ms)
12.1 [8.2–14.8]‡ 4.5 [3.9–6.1] ‡ <0.001
Nonperfused area (disc area) 44.7 ± 32.5‡ - -
Foveal thickness (μm) 557 ± 135‡ - -
†Number of patients with data. ‡Mean ± standard deviation (SD).
BRVO = branch retinal vein occlusion.
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ischemic BRVO) have increased levels of inflammatory
factors, suggesting that inflammation may promote macu-
lar edema in patients with nonischemic BRVO.
Laser flare photometry is an objective method for
evaluating the aqueous flare and cells, and it may allow
quantitative assessment of anterior chamber inflamma-
tion and breakdown of the blood–aqueous barrier [8]. It
has also been reported that the aqueous flare (photon
counts/ms) is correlated with the aqueous humor pro-
tein content (mg/ml), including total protein, albumin,
and immunoglobulin G [9,10]. Furthermore, it was re-
ported that the aqueous flare value is significantly higher
in patients with retinal vein occlusion (RVO) than in
normal controls [11,12], suggesting that an increased
flare value reflects disruption of the blood-ocular barrier
(both the blood-retinal barrier and the blood-aqueous
barrier) and inflammation in eyes with RVO. In fact, the
ratio of aqueous cells to the aqueous flare value is ap-
proximately 1:3 in BRVO patients [12]. However, the as-
sociation of inflammatory factors and the flare value
with macular edema in BRVO patients remains unclear.
We previously investigated the correlation of inflamma-
tory factors with retinal changes [13], while the correl-
ation with the aqueous flare was investigated in this
study. We also recently reported on the correlation of
inflammatory factors with the aqueous flare in patients
with CRVO [14], which is a pathologically different con-
dition from BRVO. Therefore, we evaluated the relations
between macular edema and indicators of inflammation
(aqueous flare value and vitreous fluid levels of interleu-
kin (IL)-6, monocyte chemotactic protein (MCP)-1,
VEGF, intercellular adhesion molecule (ICAM)-1, and




Undiluted vitreous fluid samples were harvested at the
start of pars plana vitrectomy (PPV) after written in-
formed consent was obtained from each subject follow-
ing an explanation of the purpose and potential adverse
effects of the procedure. This study was performed in
accordance with the Helsinki Declaration of 1975 (1983
revision). The institutional review boards of Tokyo
Women’s Medical University approved the protocol for
collection and testing of vitreous fluid samples. Con-
secutive previously untreated patients with BRVO who
presented between June 2008 and September 2011 were
screened using the criteria listed below and vitreous fluid
samples were obtained from the 28 patients who were
enrolled. The indications for PPV were: (1) clinically de-
tectable macular edema or cystoid macular edema per-
sisting for more than 3 months, (2) best-corrected visualacuity worse than 20/40 using the Snellen visual acuity
chart, (3) onset of symptoms within 1 month before
presentation, and (4) foveal thickness >250 μm by OCT.
In addition, the subjects were limited to patients who
could fix on the central landmark during optical coher-
ence tomography. Exclusion criteria were (1) previous
ocular surgery or intravitreous injection of anti-VEGF
agents or triamcinolone acetonide, (2) diabetes mellitus
with diabetic retinopathy, (3) previous retinal photo-
coagulation, (4) iris rubeosis, and (5) a history of ocular
inflammation or vitreoretinal disease. Best-corrected vis-
ual acuity was converted to the logarithm of the mini-
mum angle of resolution (LogMAR).
Twenty-eight BRVO patients and 17 control patients
with nonischemic ocular disease were enrolled (Table 1).
Vitreous fluid samples were also obtained from the 17
controls, who all had idiopathic macular hole (MH
group). None of the patients in the MH group had prolif-
erative vitreoretinopathy. PPV was performed at Tokyo
Women’s Medical University.
Fundus findings
The fundus was examined preoperatively by biomicro-
scopy with a fundus contact lens and by standard fundus
color photography. In addition, fluorescein angiography
was performed with a Topcon TRC-50EX fundus cam-
era, an image-net system (Tokyo Optical Co. Ltd.,
Japan), and a preset lens with a slit-lamp.
Preoperative fundus findings were recorded for each
subject. A masked grader independently assessed retinal
perfusion status or ischemic retinal vascular occlusion
by examination of fluorescein angiograms. The ischemic
Noma et al. BMC Ophthalmology 2014, 14:67 Page 3 of 9
http://www.biomedcentral.com/1471-2415/14/67region of the retina was measured using the public do-
main Scion Image program, as reported previously [5,6].
Optical coherence tomography (OCT) was performed
in each subject within 1 week before vitrectomy,
employing an instrument from Zeiss-Humphrey Oph-
thalmic Systems (Zeiss Stratus OCT3, Carl Zeiss Medi-
tec, Dublin, CA, USA). The fundus was scanned with
the measuring beam focused on horizontal and vertical
planes crossing the center of the fovea, which was lo-
cated by examination of the fundus photograph and by
each patient’s fixation. Cross-sectional images were col-
lected by a single experienced examiner, who continued
each examination until highly reproducible scans were
obtained. The thickness of the central fovea was defined
as the distance between the inner limiting membrane
and the retinal pigment epithelium (including any serous
retinal detachment), and was automatically measured by
computer software. The thickness of the neurosensory
retina was defined as the distance between the inner and
outer neurosensory retinal surfaces. The average pre-
operative foveal thickness was 557 ± 135 μm, with a
range of 292 to 834 μm.
Aqueous flare measurement
The aqueous flare was measured with a laser flare meter
(FC-600, Kowa Co. Ltd., Tokyo, Japan), as described pre-
viously [8]. The sensitivity and reproducibility of this
method have been confirmed by a number of studies
[8,11,12]. Measurements were performed within 1 week
before treatment. Flare values were measured at 30 mi-
nutes after dilation of the pupil with 0.5% tropicamide
and 5% phenylephrine hydrochloride. Two different ex-
aminers obtained five measurements from each eye and
the results were averaged after excluding all measure-
ments with artefacts. The laser flare meter that was
employed could measure values up to 500 photon
counts/ms in patients without hypopium or hyphema.
We performed standardization before each test. If devi-
ation was found, we adjusted the device by setting the
zero value with a built-in calibration function.
Sample collection
Samples of undiluted vitreous fluid (0.3 – 0.7 ml) were
collected at the start of vitrectomy by aspiration into a
1 ml syringe attached to the vitreous cutter before
commencing the intravitreal infusion of balanced salt so-
lution. After collection, the vitreous samples were imme-
diately transferred into sterile tubes and were stored
frozen at −80°C within 5 minutes.
Measurement of VEGF, IL-6, MCP-1, sICAM-1, and sVEGFR-2
The levels of VEGF, IL-6, MCP-1, soluble ICAM-1
(sICAM-1), and soluble VEGFR-2 (sVEGFR-2), were
measured in vitreous fluid samples from the same eye byenzyme-linked immunosorbent assay using kits for hu-
man VEGF, IL-6, MCP-1, sICAM-1, and sVEGFR-2
(VEGF, IL-6, MCP-1, and sVEGFR-2: R&D Systems,
Minneapolis, MN, USA; sICAM-1: Bender Med Systems,
Burlingame, CA, USA) [5,6,13]. The VEGF kit was able
to detect 2 of the 4 VEGF isoforms (VEGF121 and
VEGF165), probably because these 2 shorter isoforms are
secreted and the 2 longer isoforms are cell-associated.
Each assay was performed according to the manufac-
turer’s instructions. The standard solution (100 μl for
VEGF or sICAM-1, 150 μl for IL-6, 200 μl for MCP-1,
and 100 μl for sVEGFR-2) and the sample (100 μl for
VEGF, 150 μl for IL-6, 40 μl for MCP-1, 10 μl for
sICAM-1, and 10 μl for sVEGFR-2) were added to the
wells of a 96-well plate coated with the relevant mono-
clonal antibody. After incubation, the plate was washed
and an enzyme-labeled antibody was added. After fur-
ther incubation, the plate was washed again and the sub-
strate was added. The reaction was stopped by adding
the stop solution after color had been developed, and
the optical density was determined at 450 and 620 nm
using an absorption spectrophotometer (Titertek Multi-
scan MCC/340; ICN, Tokyo, Japan). The levels of these
factors in the vitreous fluid samples and plasma were within
the detection ranges of the assays, with the minimum
detectable concentration was 15.6 pg/ml for VEGF (intra-
assay coefficient of variation (CV), 5.2%; inter-assay CV,
6.6%), 0.156 pg/ml for IL-6 (intra-assay CV, 5.3%; inter-
assay CV, 6.5%), 62.5 pg/ml for MCP-1 (intra-assay CV,
4.6%; inter-assay CV, 5.8%), 3.3 ng/ml for sICAM-1 (intra-
assay CV, 5.5%; inter-assay CV, 7.6%), and 78.1 pg/ml for
sVEGFR-2 (intra-assay CV, 5.4%; inter-assay CV, 6.8%).
Statistical analysis
All analyses were performed with SAS System 9.1 soft-
ware (SAS Institute Inc., Cary, North Carolina, USA).
Data are presented as the mean ± SD or as the median
with the interquartile range or frequency. Student’s t-test
was employed to compare normally distributed unpaired
continuous variables between the two groups and the
Mann–Whitney U test was used for variables with a
skewed distribution. To examine the relations among
vitreous levels of VEGF, IL-6, MCP-1, sICAM-1, or
sVEGFR-2, the aqueous flare value, the nonperfused
area, and the foveal thickness, Spearman’s rank-order
correlation coefficients and a multiple linear regression
model were used. Two-tailed p values of less than 0.05
were considered to indicate a statistically significant
difference.
Results
The BRVO group (17 men and 11 women) was aged
71.2 ± 7.8 years (mean ± SD), while the MH group (8






















Non-perfused area (disc area)
Figure 2 Correlation between the aqueous flare value and the
nonperfused area of the retina. The aqueous flare value was
significantly correlated with the nonperfused area of the retina in
BRVO group (ρ = 0.55, P = 0.002).
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(range: 3 – 10 months) (Table 1). Seventeen of the 28
BRVO patients (61%) had hypertension and seven pa-
tients (25%) had hyperlipidemia (Table 1). Mean BCVA
was logMAR 0.77 ± 0.40. There was no significant cor-
relation between BCVA and the aqueous flare value (ρ =
0.19, P = 0.320). There were also no significant correla-
tions between BCVA and the vitreous levels of VEGF,
IL-6, MCP-1, sICAM-1, and sVEGFR-2 (ρ = 0.33, P =
0.080; ρ = 0.18, P = 0.353; ρ = 0.17, P = 0.375; ρ = −0.16,
P = 0.409; and ρ = −0.06, P = 0.747, respectively).
The aqueous flare value (median [interquartile range])
was significantly higher in the BRVO group (median:
12.1 photon counts/ms [interquartile range: 8.2 – 14.8])
than in the MH group (4.5 photon counts/ms [3.9 –
6.1], P < 0.001) (Figure 1). The aqueous flare value was
significantly correlated with the nonperfused area of the
retina in the BRVO group (ρ = 0.55, P = 0.002) (Figure 2).
The vitreous fluid concentration of VEGF was signifi-
cantly higher in the BRVO group (754 pg/ml [59.5-1760])
compared with the MH group (15.6 pg/ml [15.6-23.1])
(P < 0.001) (Table 2). Likewise, the vitreous level of IL-6
was significantly higher in the BRVO group (10.0 pg/ml
[5.43-22.5]) than in the MH group (1.04 pg/ml [0.60-1.17],
P < 0.001), as was the vitreous level of MCP-1 (BRVO
group: 1220 pg/ml [921–1925]; MH group: 411 pg/ml
[384–582], P < 0.001) (Table 2). Furthermore, the vitreous
level of sICAM-1 was significantly higher in the BRVO
























Figure 1 Aqueous flare value in the control group (macular
hole) and in the patients with branch retinal vein occlusion
(BRVO) and macurla edema. The flare value was significantly
higher in the BRVO group than in the MH group (*P < 0.001).(4.00 ng/ml [3.37-4.92], P < 0.001), as was the vitreous
level of sVEGFR-2 (BRVO group: 1600 pg/ml [1007–
1990]; MH group: 840 pg/ml [617–1067], P < 0.001)
(Table 2). There were significant correlations between the
nonperfused area of the retina and the vitreous fluid levels
of VEGF, IL-6, MCP-1, and sICAM-1 in the BRVO group
(ρ = 0.72, P < 0.001; ρ = 0.59, P = 0.002; ρ = 0.41, P = 0.034;
and ρ = 0.38, P = 0.043, respectively) (Table 3). In order to
clarify which factor (VEGF, IL-6, MCP-1, sICAM-1, or
sVEGFR-2) was most closely correlated with the nonper-
fused area of the retina, multiple linear regression analysis
with stepwise selection of variables was performed. This
analysis showed that the vitreous level of VEGF was most
strongly correlated with the nonperfused area of the ret-
ina. In the BRVO group, vitreous fluid levels of VEGF, IL-
6, MCP-1, sICAM-1, and sVEGFR-2 were significantly
correlated with the foveal thickness (ρ = 0.50, P = 0.009;Table 2 Vitreous fluid levels of factors in the two groups
BRVO group Macular hole group P value
VEGF (pg/ml) 754 [59.5–1760] 15.6 [15.6–23.1] <0.001
IL-6 (pg/ml) 10.0 [5.43–22.5] 1.04 [0.60–1.17] <0.001
MCP-1 (pg/ml) 1220 [921–1925] 411 [384–582] <0.001
sICAM-1 (ng/ml) 9.40 [6.45–14.3] 4.00 [3.37–4.92] <0.001
sVEGFR-2 (pg/ml) 1600 [1007–1990] 840 [617–1067] <0.001
Values are the median [interquartile range]. BRVO = branch retinal vein
occlusion; VEGF = vascular endothelial growth factor; IL-6 = interleukin-6; MCP-1 =
monocyte chemotactic protein-1; soluble intercellular adhesion molecule 1 =
sICAM-1; soluble vascular endothelial growth factor receptor-2 = sVEGFR-2.
Table 3 Correlations among the variables
VEGF IL-6 MCP-1 sICAM-1 sVEGFR-2
Aqueous
flare
γ=ρ value 0.54 0.56 0.52 0.47 0.20
P value 0.005 0.004 0.006 0.015 0.295
Nonperfused
area
γ=ρ value 0.72 0.59 0.41 0.38 0.18
P value <0.001 0.002 0.034 0.043 0.343
Foveal
thickness
γ=ρ value 0.50 0.54 0.43 0.49 0.38
P value 0.009 0.003 0.025 0.008 0.044
VEGF = vascular endothelial growth factor; IL-6 = interleukin-6; MCP-1 =monocyte
chemotactic protein-1; soluble intercellular adhesion molecule 1 = sICAM-1;
soluble vascular endothelial growth factor receptor-2 = sVEGFR-2;
γ=ρ = correlation coefficient.
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and ρ = 0.38, P = 0.044, respectively) (Table 3).
There were significant correlations between the aque-
ous flare value and the vitreous fluid levels of VEGF, IL-
6, MCP-1, and sICAM-1 in the BRVO group (ρ = 0.54,
P = 0.005; ρ = 0.56, P = 0.004; ρ = 0.52, P = 0.006; and ρ =
0.47, P = 0.015, respectively) (Figure 3A-D) (Table 3).
However, there was no significant correlation between
the aqueous flare value and the vitreous fluid level of
sVEGFR-2 (ρ = 0.20, P = 0.295) (Figure 3E) (Table 3). To
clarify which factor (VEGF, IL-6, MCP-1, sICAM-1, or
sVEGFR-2) was most closely correlated with the aqueous
flare value, multiple linear regression analysis with step-
wise selection of variables was performed. This analysis
revealed that VEGF was most strongly correlated with
the aqueous flare value. In addition, the aqueous flare
value was significantly correlated with the foveal thick-
ness in the BRVO group (ρ = 0.40, P = 0.037) (Figure 4).
The BRVO patients were divided into fresh BRVO
(onset < 7 months before the study) and older BRVO
subgroups for further analysis [15]. There was no signifi-
cant difference of the aqueous flare value between the
fresh BRVO subgroup (n = 21) and the older BRVO sub-
group (n = 7) (P = 0.441). There were also no significant
differences with regard to the vitreous levels of the five
factors (VEGF, IL-6, MCP-1, sICAM-1, and sVEGFR-2)
between the fresh and older subgroups (P = 0.915; P =
0.577; P = 0.524; P = 0.490; and P = 0.691, respectively).
Discussion
The Branch Vein Occlusion Study demonstrated the ef-
fectiveness of argon laser photocoagulation for BRVO,
but it was recommended that this should not be per-
formed within 3 months after the onset since spontan-
eous improvement can occur during this period [16]. It
has also been reported that the absence of posterior vit-
reous detachment can contribute to persistent macular
edema in patients with retinal vascular occlusion [17],
while Saika et al. reported the effectiveness of vitrectomy
combined with surgical posterior vitreous detachment
for macular edema in BRVO patients [18]. Moreover, ithas been reported that PPV contributes to an increase of
oxygen tension in the inner retina [19,20]. If the retinal
oxygen tension is increased by PPV, macular edema
would improve because the increase of oxygen tension
reduces VEGF production and thus decreases vascular
permeability. An increase of oxygen tension would also
alleviate autoregulatory arteriolar vasoconstriction and
reduce the hydrostatic pressure in the retinal capillaries
and venules, which would decrease water flux from the
vascular compartment to the tissue compartment and
lessen edema according to Starling’s law. Consistent with
this hypothesis, it has been reported that vitrectomy im-
proves both functional and tomographic outcomes in
BRVO patients with macular edema [21,22]. Accord-
ingly, we performed vitrectomy in patients who had
clinically detectable diffuse macular edema or cystoid
macular edema at more than 3 months after the occur-
rence of BRVO.
The present study demonstrated that the aqueous flare
value (an index of inflammation) was significantly higher
in the BRVO group than in the MH group, and the flare
value was also significantly correlated with the nonper-
fused area of the retina in the BRVO group. In addition,
the vitreous fluid levels of VEGF, IL-6, MCP-1, and
sICAM-1 were significantly correlated with the nonper-
fused area of the retina and with the foveal thickness in
the BRVO group. We previously reported that there
were no correlations between the intraocular and plasma
levels of various cytokines, which suggested that the in-
traocular elevation of cytokines was not related to break-
down of the blood-retinal barrier and/or intraocular
bleeding [5,6,13]. These findings suggest that both ische-
mia and inflammation may have an important role in
breakdown of the blood-retinal barrier and development
of macular edema.
Moreover, we found a significant correlation between
the aqueous flare value and the vitreous fluid levels of
VEGF, IL-6, MCP-1, and sICAM-1 in the BRVO group.
Miyake et al. [11] performed anterior chamber and vitre-
ous fluorophotometry in patients with RVO, and ob-
served that the fluorescein concentration was only
increased in the anterior chamber and the posterior vit-
reous, whereas its level in the middle vitreous was low
or normal. Accordingly, they concluded that the increase
of the aqueous flare in RVO patients mainly reflects dis-
ruption of the blood-aqueous barrier. Thus, the blood-
aqueous barrier may be abnormal in the anterior seg-
ment of eyes with RVO. Furthermore, Virdi et al. [23]
found an increase of fluorescein in the aqueous humor
and vascular leakage from the iris on fluorescein angiog-
raphy in patients with major branch RVO or central
RVO who had no evident iridal abnormalities or rubeo-
sis. Fluorescein leakage from the iridal vessels was also






















































































































Figure 3 (See legend on next page.)
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Figure 3 Correlations between the aqueous flare value and the vitreous fluid levels of vascular endothelial growth factor (VEGF),
interleukin (IL)-6, monocyte chemotactic protein (MCP)-1, soluble intercellular adhesion molecule 1 (sICAM-1), and soluble VEGF
receptor-2 (sVEGFR-2). There were significant correlations between the flare value and vitreous levels of VEGF (A), IL-6 (B), MCP-1 (C), sICAM-1
(D), and sVEGFR-2 (E) in the BRVO group (ρ = 0.54, P = 0.005; ρ = 0.56, P = 0.004; ρ = 0.52, P = 0.006; ρ = 0.47, P = 0.015; and ρ = 0.20, P = 0.295,
respectively).
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findings and our results suggest that the aqueous flare
value may be increased by leakage of protein from iridal
vessels after disruption of the blood-aqueous barrier due
to the effects of inflammatory factors such as VEGF, IL-
6, MCP-1, and sICAM-1.
Interestingly, we found a significant correlation be-
tween the aqueous flare value (an index of inflamma-
tion) and the foveal thickness in the BRVO group
(Figure 4). This finding is supported by a report that the
incidence of cystoid macular edema is associated with
the severity of blood-aqueous barrier disruption [24],
and also suggests that inflammation may promote macu-
lar edema in BRVO patients. As mentioned above, we
found a significant correlation between the foveal thick-
ness and the vitreous fluid levels of VEGF, IL-6, MCP-1,
and sICAM-1 in the BRVO group (Table 2). Therefore,
the correlation between aqueous flare and foveal thick-
ness in this group might suggest that these inflammatory
factors (VEGF, IL-6, MCP-1, and sICAM-1) are involved
in the development of macular edema by increasing vas-
cular permeability and/or promoting diapedesis of leu-
kocytes. Taken together, these findings suggest that, in
addition to ischemia, inflammation is involved in theFigure 4 Correlation between the aqueous flare value and the
foveal thickness. The aqueous flare value was significantly correlated
with the foveal thickness in the BRVO group (ρ = 0.40, P = 0.037).increase of vascular permeability and disruption of the
blood-aqueous barrier via release of inflammatory fac-
tors (VEGF, IL-6, MCP-1, and sICAM-1) in BRVO pa-
tients with macular edema. However, the present study
was small, so a larger prospective investigation will be
required to confirm the influence of inflammation on
macular edema associated with BRVO.
In the present study, multiple linear regression analysis
showed that VEGF was most strongly correlated with
the aqueous flare value among the five vitreous factors
(VEGF, IL-6, MCP-1, sICAM-1, and sVEGFR-2). When
VEGF binds to VEGFR-1, chemotaxis of leukocytes (in-
flammation) is induced [25]. On the other hand, when
VEGF binds to VEGFR-2, the expression of inflamma-
tory factors such as MCP-1 and ICAM-1 is enhanced via
nuclear factor-kappa B [13]. Thus, both chemotaxis and
leukocyte adhesion to the vascular endothelium are pro-
moted by VEGF, leading to inflammation, which could
explain its close relation to the aqueous flare value.
However, there was no significant correlation between
the aqueous flare value and the vitreous fluid level of
sVEGFR-2. We previously reported that the vitreous
level of sVEGFR-2 may be regulated independently of
VEGF, even though the VEGF-VEGFR-2 signaling path-
way has an essential role in regulating vascular perme-
ability [13]. Therefore, sVEGFR-2 may not directly
influence the aqueous flare value. VEGF also showed the
strongest correlation with the nonperfused area of the
retina among the factors investigated. Because VEGF
production is upregulated by retinal hypoxia in BRVO
patients with macular edema [26], this finding is consid-
ered to be reasonable.
The SCORE study [7] recently showed that intravitreal
injection of triamcinolone acetonide could improve vis-
ual acuity and macular edema in patients with BRVO.
Considering this reported efficacy of steroid therapy, a
causative role of inflammation is suggested, which is
supported by the high aqueous flare values detected in
our study. We also found that vitreous fluid levels of
VEGF, IL-6, and MCP-1 were significantly correlated
with the aqueous flare value and the severity of macular
edema in the BRVO patients, indicating that inflamma-
tory cytokines are elevated in patients with higher flare
values. Corticosteroids may not only prevent the produc-
tion of VEGF, but may also suppress various inflamma-
tory molecules (such as IL-6 and MCP-1 [27,28]) that
promote leukocyte adhesion along with breakdown of
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meability [29]. Therefore, if the aqueous flare value is
high, combining anti-VEGF therapy with intravitreal in-
jection of triamcinolone acetonide might be considered.
It was reported that 13 out of 38 patients (34.6%) had
persistent macular edema despite receiving a mean of 6.2
injections of bevacizumab [3], while 17 out of 134 patients
(12.6%) showed no improvement of visual acuity after
monthly intravitreal injection of ranibizumab (0.3 mg) for
6 months [4]. Such patients with persistent macular
edema may have low VEGF levels or high levels of other
inflammatory factors. It is also possible that patients might
have mutation of VEGFR-2 [30,31] and/or one or more of
the signal transduction factors [32]. In these patients, it
could be worthwhile to examine the severity of inflamma-
tion by measuring the aqueous flare value. Our results,
taken together with such reports, suggest that inflamma-
tory factors could be a potential target for preventing an
increase of vascular permeability in BRVO patients and
macular edema. Thus, measuring the aqueous flare value
might help to select the treatment strategy for BRVO-
associated macular edema. However, a randomized,
prospective, clinical trial of anti-VEGF therapy and/or
triamcinolone acetonide would be required to demon-
strate efficacy for macular edema associated with BRVO.
This study also had some other limitations. For ex-
ample, the vitreal levels of cytokines may be elevated
due to disruption of the blood-retinal barrier. However,
we were not able to measure total vitreous protein levels
because the vitreous samples were too small. We previ-
ously found that the vitreous level of PEDF was de-
creased in BRVO patients [33], which suggests that
levels of cytokines in the vitreous fluid are not deter-
mined by disruption of the blood-retinal barrier. In
addition, it has been reported that VEGF-A was the only
cytokine showing a significant correlation with SD-OCT
parameters (thickness of the neurosensory retina and
disruption of the ellipsoid line) [34]. However, we could
not assess the influence of the outer photoreceptor layer
on the visual prognosis because detecting the junction
between inner and outer layers was difficult with our
OCT equipment. Accordingly, the prognosis of patients
with BRVO and macular edema needs to be investigated
in more detail in the future.
Conclusions
We found that the aqueous flare value was significantly
higher in BRVO group than in the MH group, that there
was a significant correlation between the aqueous flare
value and the foveal thickness in the BRVO group, and
that vitreous fluid levels of VEGF, IL-6, MCP-1, and
sICAM-1 were significantly correlated with both the aque-
ous flare value and the foveal thickness in the BRVO
group. These findings suggest that inflammatory factors(VEGF, IL-6, MCP-1, and sICAM-1) may induce an in-
crease of vascular permeability and disrupt the blood-
aqueous barrier in BRVO patients with macular edema.
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